Eli Lilly's Zepbound is challenging Wegovy in the obesity market, while U.S. health care costs are set to rise 9% in 2025, driven by specialty drugs and inflation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback